Treatment of decrease in desire to eat with Unani medicine Safoof Hazim Kalan

Clinical validation of Unani pharmacopoeial formulation Safoof Hazim Kalan in Zof e lshteha (Anorexia)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/01/048981

Enrollment

110

Registered

2023-01-13

Start date

Unknown

Completion date

Unknown

Last updated

2023-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: R630- Anorexia

Interventions

Intervention1: Safoof Hazim Kalan : 2-5gm powder twice daily orally To be taken with water after meals for 2 weeks Control Intervention1: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of any sex in the age group 18-65 years. 2. Patients having Zof e lshteha(Anorexia) with SNAQ score

Exclusion criteria

Exclusion criteria: 1. Patients having Anorexia nervosa 2. Patients having any systemic disease,chronic debilitating disease,T.B.,Diabetes Mellitus etc. 3. Known cases of Hepatic,Renal or Cardiac Ailments 4. History of hypersensitivity to study drug or any of its ingredients. 5. History of addiction (Alcohol,Drugs) 6. Pregnant and lactating women

Design outcomes

Primary

Measure	Time frame
Improvement in sign and symptoms of Zof e lshteha (Anorexia) on the basis of improvement in the appetite for which the Simplified Nutritional Appetite Questionnaire (SNAQ)Timepoint: On baseline, 7th day and 14th day	—

Secondary

Measure	Time frame
Haematological and biochemical assessment for safety assessmentTimepoint: At baseline and end of the treatment i.e. 14th day	—

Countries

India

Contacts

Public ContactDr Pradeep Kumar

Central Council for Research in Unani Medicine (CCRUM)

ccrum507@rediffmail.com9213511298

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026